BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant  Orphan  Europe  submitted  on  5  October  2001  an  application  for  Marketing 
Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) through the 
centralised  procedure  for  Carbaglu,  which  was  designated  as  an  orphan  medicinal  product 
EU/3/00/007 on 18 October 2000.  
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur:  Prof. Cristina Sampaio  
Co-Rapporteur:  Dr. Pieter Neels  
Orphan Drugs: 
Carbaglu  was  designated  as  an  orphan  medicinal  product  on  18  October  2000,  in  the  following 
indication: Treatment of N-acetylglutamate synthase (NAGS) deficiency. 
Scientific Advice: 
The applicant did not seek scientific advice at the CPMP. 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The procedure started on 22 October 2001. 
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP  members  on 
15 January 2002.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP 
members on 17 January 2002. 
During  the  meeting  on  19  –  21  February  2002,  the  CPMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 21 February 2002. 
The applicant submitted the responses to the CPMP consolidated List of Questions on 
11 July 2002. 
The joint Rapporteur/Co-Rapporteur Assessment Report on the applicant’s responses to the List 
of Questions was circulated to all CPMP members on 3 September 2002. 
During the CPMP meeting on 17 – 19 September 2002, the CPMP adopted a list of outstanding 
issues to be addressed by the applicant in writing. The list of outstanding issues was sent to the 
applicant on 18 September 2002. 
The applicant submitted the responses to the list of outstanding issues on 1 October 2002. 
The  applicant  provided  a  letter  of  undertaking  of  the  specific  obligations  and  follow-up 
measures  to  be  fulfilled  post-authorisation  related  to  quality,  safety  and  efficacy  aspects  on 
15 October 2002. 
During the meeting on 15-17 October 2002, the CPMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation to Carbaglu on 17 October 2002. 
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 24 January 2003. 
1/1 
EMEA 2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
